(Q53354829)

English

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

0 references

anticoagulation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

venous thromboembolism

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

Elisabet Svenungsson

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

author name string

Granqvist S

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

language of work or name

0 references

publication date

1 April 1998

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

American Journal of Medicine

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

104

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

332-338

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

Clinical trials on antiphospholipid syndrome: what is being done and what is needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Antiphospholipid syndrome: five year follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Antiphospholipid and thrombosis syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

High level of anticardiolipin antibodies is an unusual finding in an unselected stroke population

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

'Primary', 'secondary' and other variants of the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900060-6

7 January 2021

Identifiers

10.1016/S0002-9343(98)00060-6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

release_m2qxr2e54relzkn2y5tynx5gnm

1 reference

https://api.fatcat.wiki/v0/release/m2qxr2e54relzkn2y5tynx5gnm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9576405

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53354829&oldid=1844505526"